Dr. Moreau on the CASSIOPEIA Trial in Transplant-Eligible Myeloma

Video

Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

For young fit patients, induction therapy with bortezomib (Velcade), thalidomide, and dexamethasone (VTd) followed by autologous stem cell transplantation (ASCT) and VTd consolidation is standard of care. In the pivotal CASSIOPEIA trial, investigators sought to enhance the current standard of care by evaluating the addition of daratumumab (Darzalex) to induction and consolidation therapy with the triplet.

In the first part of the trial, 1085 patients were randomized to receive induction and consolidation with daratumumab/VTd or VTd alone. Findings demonstrated that the rate of stringent complete response among patients treated with the quadruplet was 28.9% versus 20.3% in those treated with VTd alone. Patients who received the quadruplet also experienced an improvement in progression-free survival (HR, 0.47). Based on these data, the FDA granted a priority review to the supplemental biologics license application for the quadruplet therapy in transplant-eligible patients. The agency is expected to make its decision by September 26, 2019.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD